GlassScriptPhysician profile
Basil Peechakara
NPI 1326616699
$1,916.72
in general payments reported to CMS, 2019-2025
19 companies · $905 in 2025
The $905 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $223 · 2023: $240 · 2024: $548 · 2025: $905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,336 · Travel and Lodging: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,336.41 |
| Travel and Lodging | $356.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuropace, INC. | $356.96 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $252.51 | 2022-2023 | Andexxa |
| Ucb, INC. | $243.50 | 2024-2025 | Briviact |
| Neurocrine Biosciences, INC. | $193.32 | 2024 | Ingrezza |
| Jazz Pharmaceuticals INC. | $126.00 | 2025 | |
| Neurelis, INC. | $122.76 | 2025 | Valtoco |
| Abbvie INC. | $120.18 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $118.12 | 2024-2025 | Zeposia |
| Livanova USA, INC. | $94.94 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Takeda Pharmaceuticals U.S.A., INC. | $44.25 | 2022-2024 | Hyqvia |
| Biogen, INC. | $43.91 | 2024-2025 | Tysabri, Vumerity |
| Biohaven Pharmaceutical Holding Company LTD. | $41.44 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $34.55 | 2024 | Ajovy |
| Catalyst Pharmaceuticals, INC. | $29.14 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $21.54 | 2025 | Nuedexta |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $20.99 | 2024 | Xcopri |
| Merck Sharp & Dohme LLC | $18.98 | 2022 | |
| Lundbeck LLC | $17.47 | 2025 | Vyepti |
| Csl Behring | $16.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basil Peechakara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.